Gemphire Therapeutics (GEMP) Earns Daily Coverage Optimism Score of 0.09
News articles about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9752298337593 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Gemphire Announces Pricing of $22 Million Public Offering of Common Stock (finance.yahoo.com)
- BRIEF-Gemphire Announces Proposed Public Offering Of Common Stock (reuters.com)
- Gemphire Announces Proposed Public Offering of Common Stock (finance.yahoo.com)
- Head-To-Head Analysis: Gemphire Therapeutics (GEMP) vs. TESARO (TSRO) (americanbankingnews.com)
- BRIEF-Gemphire Announces Initiation Of Phase 2A Clinical Trial Of Pediatric NAFLD (reuters.com)
Gemphire Therapeutics (NASDAQ:GEMP) traded down $2.36 during mid-day trading on Thursday, reaching $6.27. The company had a trading volume of 1,724,000 shares, compared to its average volume of 109,148. The company has a market cap of $93.68, a PE ratio of -1.86 and a beta of 3.90. Gemphire Therapeutics has a fifty-two week low of $6.16 and a fifty-two week high of $21.59. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17.
GEMP has been the topic of several recent research reports. Canaccord Genuity restated a “buy” rating on shares of Gemphire Therapeutics in a research note on Friday, October 13th. Zacks Investment Research upgraded Gemphire Therapeutics from a “sell” rating to a “hold” rating and set a $11.00 price target on the stock in a research note on Monday, October 16th. Roth Capital initiated coverage on Gemphire Therapeutics in a research note on Thursday, October 19th. They issued a “buy” rating and a $30.00 price target on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $22.00 price target on shares of Gemphire Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target (up previously from $21.00) on shares of Gemphire Therapeutics in a research note on Tuesday, November 14th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.17.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.